is dgl a blood thinner?

The risk of bleeding was comparable to that of warfarin, according to data presented Monday at the American College of Cardiology meeting.

The drug profile is interesting and the preliminary results look promising, but they need to be tested in a Phase III study, according to Dr. Michael Ezekowitz.

The safety profile seems good.

The vice president of the Lankanau Institute for Medical Research said that there was no evidence that the drug was toxic to the body.

Several laboratories, including Boehringer Ingelheim, Bristol-Myers Squibb Co, and Pfizer Inc, are working on a new class of anticoagulants called factor Xa.

Analysts said that a daily pill could be better than all the other drugs that are supposed to replace warfarin, which is difficult to use.

Unlike the Xa drugs, betrixaban is not eliminated by the kidneys.

It can be used in patients with advanced kidney disease. These patients have not been excluded from other drug trials.

Atrial fibrillation is an irregular heart rhythm that increases the risk of stroke and was experienced by 74 year olds in Phase III.

The patients had an increased risk of stroke.

The main goal of the study was to measure the recurrence of clinically relevant or heavy bleeding, as this is the most significant setback that can occur with anticoagulants.